4d Pharma Share Discussion Threads

[devonlad] 10/6/2021 18:22

Three is a pattern there stig, three partnered ici trials if it happens will light the fuse. Think they might be waiting for the next read out.

[the stigologist] 10/6/2021 18:16

Given a course of treatment costs c.$100k per patient it's not in the interests of Bristol Myers or Merck to fund large trials which aren't going anywhere (a trial of 100 people would be $10m. Imagine if it went to a Phase III with 1000 patients you'd be looking at spending $100m)

Thus when Merck stopped backing Evelo TNBC combo trial 4D added TNBC indication to their combo trial with Merck

Similarly I guess BMS will be looking to partner Opdivo with A.N.Other microbiome strain thus they must have told Seres they would no longer back their trial

[1airbag] 10/6/2021 17:15

Wonder why they pulled out of the Oncology work…? Any guesses?

;-)

[mickinvest] 10/6/2021 16:36

No mention of 4D but interesting article regarding Seres and ICI's.




Seres Bolsters Rationale Behind GVHD, Cancer Programs at ASCO Meeting

Published: Jun 10, 2021 By Mark Zipkin


While no microbiome therapies have yet been approved for any indication, pharmaceutical companies have taken notice of their relative clinical success and are partnering with microbiome companies in another hot area, immune checkpoint inhibitors (ICIs).

Recent clinical studies have bolstered a growing body of evidence that the gut microbiome can potentiate ICIs, which are known for their impressive anticancer response in a small subset of patients. Seres was an early player in this space as well, but recently announced it was discontinuing its SER-401 program, ending new enrollment in a Phase I combination trial with the anti-PD-1 ICI Opdivo (nivolumab) for patients with metastatic melanoma.

Matthew Henn, CSO and executive vice president of R&D at Seres, said the company remains very interested in cancer and ICIs.

“We have developed new research programs at Seres focused on increasing efficacy, but also ameliorating the off-target toxicities as well,” Henn said.

The SER-401 trial is still generating data as well, he said, and together have allowed the company to prioritize a rationally designed cultivated therapeutics program.

[trumpingtonsmythe] 10/6/2021 14:51

You are all correct, I will filter as 95% became 98% in the blink of an eye. Clearly some sort of delusional individual.

[the stigologist] 10/6/2021 14:46

Always leave a little on the table for the next man

[little minx] 10/6/2021 14:27

Surely you are waiting for £10 lol

[mr roper] 10/6/2021 14:20

I’ll look to top slice about 830p

[g2theary] 10/6/2021 14:10

Yesterday's buy looking even better... I'll look to top slice above 130 :)

[rjcdc] 10/6/2021 13:46

Really trying hard not to let it get above £1…

Cd end up a lot higher today

[mark10101] 10/6/2021 13:45

Devonlad, quite happy for bots doing their thing, they are part of the equation that I think will cause 4D to make some pretty sharp moves. All eyes on the US open for a high volume up day.

[bluebear1] 10/6/2021 13:40

Why.I've been correct 98%.Please buy more.

[devonlad] 10/6/2021 13:27

12k already traded in LBPS pre market, everage volume is just over 20k, up just under 7% before the open. BOTS trying to hold £1.

[thepaddedcell] 10/6/2021 12:39

Buy and hold will reward us all better ! Have the courage of your convictions !

[pistolwhip] 10/6/2021 12:36

Don't even bother TrumpingtonSmythe....no one else is. The intentions have been obvious from the outset.

[bluebear1] 10/6/2021 12:25

Please continue to buy.Thank you

[thepaddedcell] 10/6/2021 12:08

Some people on here talk a lot of Kaka. Sounds like some have missed the boat, again !

[bluebear1] 10/6/2021 11:53

Thank you for buying

[bluebear1] 10/6/2021 11:24

Keep buying please

[stephen uptrend] 10/6/2021 11:06

Just added 20,000 shares

Too cheap down here

[bluebear1] 10/6/2021 10:47

Buy please